SGLT2 Inhibitor Use Associated With Reduced Risk of Dementia, Parkinson Disease

 With your increased risk of Parkinsons and dementia post stroke, what is your doctor's position on this for off-label use? Does your competent? doctor even know and think about these issues?

With your elevated chances of dementia post stroke,  your competent? doctor is responsible for preventing that! Have they taken on that responsibility? Or are they DOING NOTHING?

With your chances of getting dementia post stroke you need solutions. YOUR DOCTOR IS RESPONSIBLE FOR PREVENTING THIS!

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

Parkinson’s Disease May Have Link to Stroke March 2017

 

The latest here:

SGLT2 Inhibitor Use Associated With Reduced Risk of Dementia, Parkinson Disease

Use of sodium-glucose cotransporter-2 (SGLT2) inhibitors among patients with type 2 diabetes significantly reduced the risk of neurodegenerative disorders, independent of various factors including comorbidities and bioclinical parameters, according to a nationwide population-based study published in the journal Neurology.

“We know that these neurodegenerative

click to scroll down to continue reading the article

article continues here

diseases like dementia and Parkinson’s disease are common and the number of cases is growing as the population ages, and people with diabetes are at increased risk of cognitive impairment, so it’s encouraging to see that this class of drugs may provide some protection against dementia and Parkinson’s disease,” said Minyoung Lee, MD, Yonsei University College of Medicine, Seoul, South Korea.

The retrospective study looked at people with type 2 diabetes who started diabetes medication between 2014 and 2019 in South Korea. Patients taking SGLT2 inhibitors were matched with patients taking other oral diabetes drugs. Those taking the SGLT2 inhibitors were followed for an average of 2 years and those taking the other drugs were followed for an average of 4 years.

Among the 358,862 participants with an average age of 58, a total of 6,837 people developed dementia or Parkinson’s disease during the study.

For Alzheimer’s disease, the incidence rate for people taking SGLT2 inhibitors was 39.7 cases per 10,000 person-years, compared with 63.7 cases for those taking other diabetes drugs. For vascular dementia, the incidence rate was 10.6 cases per 10,000 versus 18.7, respectively. For Parkinson’s disease, the incidence rate for those taking the SGLT2 inhibitors was 9.3 cases per 10,000, compared with 13.7 for those taking the other drugs.

After researchers adjusted for other factors that could affect the risk of dementia or Parkinson’s disease, such as complications from diabetes and medications, they found that SGLT2 inhibitor use was associated with a 20% reduced risk of Alzheimer’s disease and a 20% reduced risk of Parkinson’s disease. Those taking SGLT2 inhibitors had a 30% reduced risk of developing vascular dementia.

“The results are generally consistent even after adjusting for factors like blood pressure, glucose, cholesterol, and kidney function,” Dr. Lee said. “More research is needed to validate the long-term validity of these findings.”

He noted that since participants were followed for less than 5 years at the most, it’s possible that some participants would later develop dementia or Parkinson’s disease.

Reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209805

SOURCE: American Academy of Neurology